Beijing-based MegaRobo, which applies robotics and AI to life sciences research, has raised a ~$300M Series C led by GGV Capital and Asia Investment Capital
Six-year-old biotech startup MegaRobo Technologies has raised about $300 million from investors including an arm of Goldman Sachs Group Inc. …
Context & Ripple Effects
GGV Capital's lead in MegaRobo's ~$300M Series C extends a pattern: the same firm led Beijing warehouse-robot maker Geek+'s $150M Series C1 in 2019, making this its second major bet on Chinese robotics applied to a specific vertical — here, lab automation for life sciences rather than logistics. The participation of a Goldman Sachs arm alongside Asia Investment Capital marks institutional crossover money entering the category.
Read against later coverage, the 2022 round is an early data point in a steepening curve: by late 2025 and 2026, Chinese robotics rounds had grown an order of magnitude larger, with Galbot raising over $300M at a $3B valuation and AI² Robotics pulling in ~$736M at a ~$2.9B valuation.
First-order effects
- MegaRobo gains roughly $300M to scale its robotics-and-AI platform for life sciences research, with GGV Capital, Asia Investment Capital, and a Goldman Sachs arm now on the cap table.
- GGV Capital now holds parallel positions in Chinese robotics across two verticals — logistics via Geek+ and lab automation via MegaRobo — concentrating its exposure in Beijing-based operators.
Second-order effects
- Competing life-sciences automation startups face a newly capitalized rival whose funding matches the entire Series B era of Chinese robotics — Roobo's $53M raise in 2017 was a landmark then, MegaRobo's round alone is nearly six times that.
- The presence of a Goldman Sachs arm signals Western institutional capital still flowing into Chinese robotics despite geopolitical friction elsewhere in the tech relationship, potentially normalizing similar crossover participation for peers.
Third-order effects
- If the trajectory from MegaRobo's 2022 round to the 2025–26 mega-rounds holds, Chinese robotics consolidates around heavily capitalized platform players, raising the funding bar for any new entrant in applied automation.
- Vertical-specific robotics — labs, warehouses — appears to function as a proving ground from which companies graduate into broader ambitions, suggesting today's application-focused rounds seed tomorrow's general-robotics contenders.
The trend: Chinese robotics funding is escalating from tens-of-millions vertical-application rounds toward multi-hundred-million platform-scale financings, with repeat backers like GGV Capital anchoring the cycle.